CompanyGraph
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- PositionDebt-to-equity is 0×, lower than 95% of its Medical Instruments & Supplies peers (median 0.23×)
- FinancialsHigh structural barrier to entry
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.64%
Annual Rate
CNY 0.50Paid annual
Payout Ratio
48.1%Sustainable
Payback Period
59.8 yr
Last Ex-Dividend
May 27, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.00BCNY895.77M · vs all stocks (USD)
Trailing P/E
28.64xvs Medical Instruments & Supplies peers
Revenue (TTM)
884.86MCNY132.04M · vs all stocks (USD)
Profit Margin
23.56%vs Medical Instruments & Supplies peers
Beta
0.3310xvs all stocks
52-Week Change
-34.60%vs all stocks
Market Capitalization
6.00BCNY895.77M · vs all stocks (USD)
Enterprise Value
4.72BCNY704.32M · vs all stocks (USD)
Trailing P/E
28.64xvs Medical Instruments & Supplies peers
Forward P/E
25.72xvs Medical Instruments & Supplies peers
Price to Sales (TTM)
6.78xvs Medical Instruments & Supplies peers
Price to Book (MRQ)
3.37xvs Medical Instruments & Supplies peers
Enterprise to Revenue
5.33xvs Medical Instruments & Supplies peers
Enterprise to EBITDA
18.39xvs Medical Instruments & Supplies peers
Gross Margin
55.79%vs Medical Instruments & Supplies peers
Profit Margin
23.56%vs Medical Instruments & Supplies peers
Operating Margin
25.27%vs Medical Instruments & Supplies peers
Return on Assets (TTM)
6.88%vs Medical Instruments & Supplies peers
Return on Equity (TTM)
12.44%vs Medical Instruments & Supplies peers
Revenue (TTM)
884.86MCNY132.04M · vs all stocks (USD)
Revenue per Share (TTM)
4.41CNYUpdated Sep 21, 2026Quarterly Revenue Growth
10.50%vs Medical Instruments & Supplies peers
Gross Profit (TTM)
492.46MCNY73.48M · vs all stocks (USD)
EBITDA (TTM)
221.83MCNY33.10M · vs all stocks (USD)
Net Income (TTM)
208.49MCNY31.11M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.60%vs Medical Instruments & Supplies peers
Operating Cash Flow (TTM)
264.96MCNY39.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
90.72MCNY13.54M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.5000CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
1.64%vs all stocks
Payout Ratio
48.14%vs Medical Instruments & Supplies peers
Minority Interest (Equity)
41.12MCNYFY2025 · Dec 31, 2025Revenue
827.50MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
352.94MCNYFY2025 · Dec 31, 2025Gross Profit
474.56MCNYFY2025 · Dec 31, 2025Operating Income
209.67MCNY31.29M · vs all stocks (USD)
Pre-tax Income
233.61MCNYFY2025 · Dec 31, 2025Income Tax Expense
29.89MCNYFY2025 · Dec 31, 2025Net Income
203.72MCNYFY2025 · Dec 31, 2025EBIT
234.82MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
262.15MCNYFY2025 · Dec 31, 2025Research & Development
45.66MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
113.39MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
494.54KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.21MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.9611CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.9611CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
200.73MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
200.73MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
203.72MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-10.80MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
249.71MCNYFY2025 · Dec 31, 2025Free Cash Flow
153.09MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
742.93MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
203.72MCNYFY2025 · Dec 31, 2025Other Non-cash Items
13.92MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
42.57MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.50MCNYFY2025 · Dec 31, 2025Capital Expenditures
-96.62MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.96BCNYFY2025 · Dec 31, 2025Sale of Investments
2.35BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-710.39MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
48.16MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-3.13MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-101.38MCNYFY2025 · Dec 31, 2025Other Financing Charges
-3.94MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-60.29MCNYFY2025 · Dec 31, 2025Shares Outstanding
201.51MSharesUpdated Sep 21, 2026Float Shares
73.62MSharesUpdated Sep 21, 2026% Held by Insiders
64.11%vs all stocks
% Held by Institutions
6.59%vs all stocks
Total Cash (MRQ)
1.29BCNY192.97M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.44CNYUpdated Sep 21, 2026Total Debt (MRQ)
3.02MCNY450.90K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0017xvs Medical Instruments & Supplies peers
Current Ratio (MRQ)
8.98xvs Medical Instruments & Supplies peers
Book Value per Share (MRQ)
8.84CNYUpdated Sep 21, 2026Total Assets
2.02BCNY301.48M · vs all stocks (USD)
Total Current Assets
1.66BCNYFY2025 · Dec 31, 2025Total Liabilities
216.82MCNYFY2025 · Dec 31, 2025Total Non-current Assets
357.15MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
13.63MCNYFY2025 · Dec 31, 2025Total Current Liabilities
203.18MCNYFY2025 · Dec 31, 2025Cash
739.76MCNYFY2025 · Dec 31, 2025Cash Equivalents
3.17MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
742.93MCNYFY2025 · Dec 31, 2025Other Short-term Investments
661.28MCNYFY2025 · Dec 31, 2025Accounts Receivable
92.50MCNYFY2025 · Dec 31, 2025Inventory
95.03MCNYFY2025 · Dec 31, 2025Accounts Payable
51.43MCNYFY2025 · Dec 31, 2025Short-term Debt
47.34MCNYFY2025 · Dec 31, 2025Other Current Liabilities
33.56MCNYFY2025 · Dec 31, 2025Long-term Debt
2.14MCNYFY2025 · Dec 31, 2025Common Stock (Book)
201.51MCNYFY2025 · Dec 31, 2025Retained Earnings
542.20MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.80BCNY269.13M · vs all stocks (USD)
Treasury Stock
30.00MCNYFY2025 · Dec 31, 202552-Week Low
26.05CNYUpdated Sep 21, 202652-Week High
49.90CNYUpdated Sep 21, 202652-Week Change
-34.60%vs all stocks
Beta
0.3310xvs all stocks
50-Day MA
29.20CNYUpdated Sep 21, 2026200-Day MA
34.68CNYUpdated Sep 21, 2026Avg 10-Day Volume
1.39MSharesUpdated Sep 21, 2026Avg 30-Day Volume
1.89MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
1.04CNYUpdated Sep 21, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Medical Instruments & Supplies peers (median 0.23×)Notable
Debt-to-equity: 0.00Industry median: 0.23Industry P5: 0.00Peers compared: 62.00
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.51
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Quakesafe Technologies Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Solareast Holdings Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Zhejiang Kaier New Materials Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Total Energy Services Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Anhui Higasket Plastics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Zhenjiang Dongfang Electric Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Shanghai Hajime Advanced Materials Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Wus Printed Circuit Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Suqian Unitech Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Fujian Furi Electronics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Vedant Fashions Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity ConfigurationMulti-Year FCF With Growth And Margin
Ovctek China Inc.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity ConfigurationMulti-Year FCF With Growth And Margin
Hangzhou XZB Tech Co., Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity ConfigurationMulti-Year FCF With Growth And Margin